Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma

Clinical Cancer Research

Volumn 18, Issue 20, 2012, Pages 5690-5700

  Lau, Diana T ^a   Hesson, Luke B ^b   Norris, Murray D ^a   Marshall, Glenn M ^a,c   Haber, Michelle ^a   Ashton, Lesley J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; GAMMA GLUTAMYL HYDROLASE; MYOGENIC DIFFERENTIATION 1 PROTEIN; NEUTROPHIC TYROSINE KINASE RECEPTOR 1 PROTEIN; PROTEIN DNAJC15; PROTEIN PYCARD; PROTEIN TNFRSF10D; THROMBOSPONDIN 1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CAUSE OF DEATH; CELL CYCLE REGULATION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE FUNCTION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEWBORN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

ADOLESCENT; APOPTOSIS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; PROMOTER REGIONS, GENETIC;

EID: 84867537621     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0294     Document Type: Article

References (51)

1. Brodeur GM, Maris JM.Neuroblastoma. In:Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 933-70.
2. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80. (Pubitemid 37009955)
3. Brodeur GM, Seeger RC. Gene amplification in human neuroblastomas: basic mechanisms and clinical implications. Cancer Genet Cytogenet 1986;19:101-11. (Pubitemid 16149777)
4. Hamid A, Wani NA, Kaur J. Newperspectives on folate transport in relation to alcoholism-induced folate malabsorption-association with epigenome stability and cancer development. FEBS J 2009;276:2175-91.
5. Ulrich CM, Potter JD. Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 2006;15:189-93. (Pubitemid 43342163)
6. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 2002;132:2350S-5S. (Pubitemid 34848106)
7. Jacob RA, Gretz DM, Taylor PC, James SJ, Pogribny IP, Miller BJ, et al. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J Nutr 1998;128:1204-12. (Pubitemid 28317688)
8. Crott JW, Liu Z, Keyes MK, Choi SW, Jang H, Moyer MP, et al. Moderate folate depletion modulates the expression of selected genes involved in cell cycle, intracellular signaling and folate uptake in human colonic epithelial cell lines. J Nutr Biochem 2008;19:328-35. (Pubitemid 351503765)
9. Ciappio ED, Mason JB, Crott JW. Maternal one-carbon nutrient intake and cancer risk in offspring. Nutr Rev 2011;69:561-71.
10. Dizik M, Christman JK, Wainfan E. Alterations in expression and methylation of specific genes in livers of rats fed a cancer promoting methyl-deficient diet. Carcinogenesis 1991;12:1307-12.
11. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2000;130:129-32. (Pubitemid 30073783)
12. Christman JK, Sheikhnejad G, Dizik M, Abileah S, Wainfan E. Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency. Carcinogenesis 1993;14:551-7. (Pubitemid 23149981)
13. Pogribny IP, Miller BJ, James SJ. Alterations in hepatic p53 gene methylation patterns during tumor progression with folate/methyl deficiency in the rat. Cancer Lett 1997;115:31-8. (Pubitemid 27139853)
14. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28. (Pubitemid 34587077)
15. Ashton LJ, Murray JE, Haber M, Marshall GM, Ashley DM, Norris MD. Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma. Pharmacogenet Genomics 2007;17:709-17. (Pubitemid 47263066)
16. Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, Van Criekinge W. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 2008;36: D842-6. (Pubitemid 351149833)
17. Mikeska T, Candiloro IL, Dobrovic A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics 2010;2:561-73.
18. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia E, Wu B, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006;16:383-93. (Pubitemid 43327509)
19. Wilop S, Fernandez AF, Jost E, Herman JG, Brummendorf TH, Esteller M, et al. Array-based DNA methylation profiling in acute myeloid leukaemia. Br J Haematol 2011;155:65-72.
20. Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E, et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009;113:2488-97.
21. Ambros PF, Ambros IM, Brodeur GM,Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009;100:1471-82.
22. Decock A, Ongenaert M, Vandesompele J, Speleman F. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings. Epigenetics 2011;6:962-70.
23. Yie SM, Hu Z. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies. Histol Histopathol 2011;26:409-20.
24. Anderton J, Lindsey J, Lusher M, Gilbertson R, Bailey S, Ellison D, et al. Global analysis of the medulloblastoma epigenome identifies disease-subgroup- specific inactivation of COL1A2. Neuro Oncol 2008;10: 981-94.
25. Lindsey JC, Lusher ME, Strathdee G, Brown R, Gilbertson RJ, Bailey S, et al. Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer 2006;118:346-52. (Pubitemid 41779073)
26. Olk-Batz C, Poetsch AR, Nollke P, Claus R, Zucknick M, Sandrock I, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 2011;117:4871-80.
27. Ehrlich M, Jiang G, Fiala E, Dome JS, Yu MC, Long TI, et al. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 2002;21:6694-702. (Pubitemid 35177050)
28. Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, et al. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res 2001;61:4258-65. (Pubitemid 32720997)
29. Debiec-Rychter M, Alwasiak J, Papierz W, Liberski PP. Expression of N-myc, c-myc and c-erbB-1 proto-oncogenes in cerebral primitive neuroectodermal tumors (PNET). Folia Neuropathol 1994;32:229-31.
30. Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, et al. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 2010;16:2036-45.
31. Wu R, Lin L, Beer DG, Ellenson LH, Lamb BJ, Rouillard JM, et al. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am J Pathol 2003;162:1603-10. (Pubitemid 36512843)
32. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992;52:1364-8.
33. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54. (Pubitemid 23084339)
34. Grau E, Martinez F, Orellana C, Canete A, Yanez Y, Oltra S, et al. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 2010;50:153-62.
35. Banelli B, Gelvi I, Di Vinci A, Scaruffi P, Casciano I, Allemanni G, et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005;24:5619-28. (Pubitemid 43119355)
36. Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S, et al. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res 2008;14:7011-9.
37. DeVos L, Chanson A, Liu Z, Ciappio ED, Parnell LD, Mason JB, et al. Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations. Am J Clin Nutr 2008;88:1149-58.
38. Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004;96:1208-19. (Pubitemid 39232712)
39. Eklof V, Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Palmqvist R. The reduced folate carrier (RFC1) 80G > A and folate hydrolase 1 (FOLH1) 1561C > T polymorphisms and the risk of colorectal cancer: a nested case-referent study. Scand J Clin Lab Invest 2008;68: 393-401.
40. Edmondson DG, Olson EN. A gene with homology to the myc similarity region of MyoD1 is expressed during myogenesis and is sufficient to activate the muscle differentiation program. Genes Dev 1989;3: 628-40.
41. Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003;63:6299-310. (Pubitemid 37255177)
42. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004;10:8493-500. (Pubitemid 40053415)
43. Jones PA, Wolkowicz MJ, Rideout WM III, Gonzales FA, Marziasz CM, Coetzee GA, et al. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc Natl Acad Sci U S A 1990;87:6117-21.
44. Dias P, Parham DM, Shapiro DN, Webber BL, Houghton PJ. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol 1990;137: 1283-91.
45. Yang Q, Tian Y, Ostler K, Chlenski A, Guerrero L, Salwen H, et al. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer 2010;10:286.
46. Gonzalez-Gomez P, Bello M, Lomas J, Arjona D, Alonso M, Aminoso C, et al. Aberrant methylation of multiple genes in neuroblastic tumours: relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 2003;39:1478-85. (Pubitemid 36773792)
47. Retaux S, Rogard M, Bach I, Failli V, Besson MJ. Lhx9: a novel LIM-homeodomain gene expressed in the developing forebrain. J Neurosci 1999;19:783-93. (Pubitemid 29036029)
48. Vladimirova V, Mikeska T, Waha A, Soerensen N, Xu J, Reynolds PC, et al. Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia 2009;11:700-11.
49. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005;65:828-34. (Pubitemid 40216441)
50. Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett 2007;247: 253-8. (Pubitemid 46240612)
51. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66. (Pubitemid 37328861)